Related Experiment Video

Updated: Jan 1, 2026

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.9K

A New CDK9 Inhibitor on the Block to Treat Hematologic Malignancies

Clara Alcon1, Albert Manzano-Muñoz1, Joan Montero2

  • 1Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|December 18, 2019
PubMed

Insights

AZD4573, a CDK9 inhibitor, effectively reduces cancer-promoting genes like MCL-1 in preclinical models of blood cancers. Further clinical trials are recommended for this agent, both alone and with BH3 mimetics, to overcome drug resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinase 9 (CDK9) plays a crucial role in regulating gene expression, including oncogenes like MCL-1.
  • MCL-1 is frequently overexpressed in hematologic malignancies, contributing to cancer cell survival and drug resistance.

Purpose of the Study:

  • To evaluate the efficacy of AZD4573, a novel CDK9-specific inhibitor, in preclinical models of hematologic malignancies.
  • To explore the potential of AZD4573 as a monotherapy and in combination with BH3 mimetics to overcome treatment resistance.

Main Methods:

  • Treatment of hematologic malignancy preclinical models with AZD4573.
  • Assessment of gene expression changes, focusing on cancer-promoting genes such as MCL-1.
  • Evaluation of combination therapy with BH3 mimetics.

Main Results:

  • CDK9 inhibition by AZD4573 effectively suppressed cancer-promoting gene expression, including MCL-1.
  • AZD4573 demonstrated significant efficacy in preclinical models of hematologic malignancies.

Conclusions:

  • AZD4573 is a promising clinical candidate for treating hematologic malignancies.
  • Combination therapy with BH3 mimetics may enhance efficacy and prevent resistance to AZD4573 treatment.

More Related Videos

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment11:11

Isolation and Expansion of Cytotoxic Cytokine-induced Killer T Cells for Cancer Treatment

Published on: January 24, 2020

11.4K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
394